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most common isolates were yeast like fungi- 14 strains (99%). The
dominant strains from Candida genus were C. glabrata 4 (28.5%),
C. krusei 4 (28.5%), C. albicans 2 (14.3%), C. tropicalis 1 (7.2%),
C. parapsilosis 1 (7.2%). Other fungal strains: Cryptococcus neo-
formans isolated in 2 cases (14.3%) and Aspergillus fumigatus. 1
strain- 6.7% out of the total number of cultures. The susceptibil-
ity of isolates for Amphotericine B and Voriconazole was 100%. In
13 strains which were tested for Itraconazole, 6 (46%) were re-
sistant, the 16.7% of analyzed spesies were Flukonazole resistant.
100% of C. glabrata isolates were susceptible for Caspofungin and
Posaconazole.
Conclusions: The performed analyses indicated that yeast like
fungi had the highest contribution in fungemias (99%). The main
etiological factors of fungemia in immunodeficient patients were
non-albicans species 66.7% 3. The dominant species from Can-
dida genus with increased resistance for antifungal agents were
C. glabrata 33.3% and C.krusei 33.3%. The most efficient antifun-
gal agents were in vitro Amphotericin B and Voriconazole.
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treated with Surgical Resection and Posaconazole
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31-year-old African American male patient previously healthy and
a retired professional football player presented to his primary care
physician on early August of 2007 complaining of cough, and ini-
tially treated for a suspected upper respiratory infection with cef-
podoxime and doxycycline without any improvement. On August
20, 2007, he developed hemoptysis and was found to have ane-
mia (8.2 g/dL), thrombocytopenia (23,000/mm3) and leukocytosis
(14.500/mm3) with 50% blasts. A bone marrow biopsy on August
21, 2007 was consistent with Acute Promyelocytic Leukemia (APL)
and started induction chemotherapy on August 24, 2007 with ATRA,
Idarubicin, and Dexamethasone until August 30, 2007 when Idaru-
bicin and Dexamethasone were discontinued and was kept on ATRA.
He became neutropenic on August 27, 2007 and on September 9,
2007 developed fever associated with a right middle lobe consoli-
dation and a right pleural effusion and thoracentesis cultures were
negative. He remained neutropenic until September 17, 2007 and
during this time received broad spectrum antibiotics and antifun-
gals including Caspofungin from August 24, 2007 to September 6,
2007, Voriconazole from September 6, to September 10, 2007 and
Ambisome from September 10, 2007 until October 9, 2007. On
September 21, 2007 and due to the progression of the infiltrate,
he had a bronchoscopy and a transbronchial biopsy was consis-
tent with Angioinvasive Zygomycosis and was kept on intravenous
Ambisome and Posaconazole was added. On October 1, 2007, he
underwent a right exploratory thoracotomy with decortication of
the right lower lobe and partial parietal pleurectomy and right
middle lobectomy and the pathologic report showed Angioinvasive
Zygomycosis, however, the fungal cultures were negative. He re-
mained on intravenous Ambisome and Posaconazole and fourteen
days later was dismissed home on Posaconazole with the intention
to continue this agent while on therapy for the APL and to extend
the treatment for one additional year post-remission. PCRs for APL
in peripheral blood have been negative since October 15, 2007.
Conclusion: He is currently on therapy for the APL with ATRA,
Methotrexate, and 6-Mercaptopurine and the plan is to extend
this regimen for two years. He was re-evaluated on February 5,
2008 and was asymptomatic and follow-up chest x-rays have con-
tinued to show signs of resolution and is now only consistent with
post-operative changes. He has continued to tolerate Posaconazole
well.
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Background: Infections by Zygomycetes (class Zygomycetes, most
infections by fungi of the Mucorales order) are rare emerging
mould infections found almost exclusively among immunocompro-
mised patients (malignant diseases, after haematopietic stem cell
transplantation (HSCT) or solid organ transplantation, neutrope-
nia, iron overload, diabetes mellitus, drug addiction ...). In the
last decades the number of referred cases in English written lit-
erature increased. The outcome of treatment is slowly improving
due to aggressive surgical treatment together with modern antimy-
cotic treatment. In spite of that the mortality of pulmonary form
remains over 80%.
Materials: We summarized the invasive infections by Zygomycetes
in a 33 bed (21 standard beds, 8 intensive care beds, 4 transplant
beds) tertiary hematooncological centre in Prague, Czech Republic.
Methods: A prospective monitoring of mould infections in the time
period 1/2003-12/2007 was used and we choose only the proven
cases (according to EORTC-MSG criteria).
Results: There were two clusters of infections by Zygomycetes in
60 months – 4 proven cases in 1-4/2003, all caused by Rhizomucor
pusillus, which had been identified in hospital environment be-
fore the clinical cases appeared. 2 proven cases 12/2005-1/2006
were identified by histology without further specification by cul-
ture. Four of 6 patients were after HSCT and 2 after therapy for
acute leukemias. Five of 6 patients developed pulmonary form,
one of HSCT patients developed disseminated form. 4 patients died
from the progression of mycosis, one died from the relapsing ma-
lignancy, one patient lives without any sign of fungal infection.
Conclusions: The aforementioned cases support the evidence of
poor outcome of zygomycoses in haematooncology patients. The
predominance of pulmonary form and high mortality in this patient
group is in concordance with literature. The clustering of cases
to two time periods and identification of Zygomycetes in hospital
environment prior to the first period support the idea of higher
vigilance and/or preventive measures (change in antimycotic pol-
icy or temporary closure of the unit) when these extremely dan-
gerous fungi are found in the environment of immunocompromised
patient.
66
Immunocompromised Patients with Possible Sphenoid Sinus
Aspergilloma the Role of Detection of Aspergillus Antigen
Galactomannan
Polyzo Kazila1, Eleni Kaitsa1, Soultana Kostopoulou1,
Evaggelos Antonakis1, Vasiliki Gastari2, Eirini Katodritou2,
Konstantinos Zervas2. 1Laboratory of Microbiology, “Theagenio"
Cancer Hospital, Thessaloniki Greece; 2Haematology Clinic,
“Theagenio" Cancer Hospital, Thessaloniki Greece
Background: The invasive infections from Aspergillus are a major
cause of morbidity and mortality in immunocompromised patients.
The diagnosis is based on the histological tests and the growth of
the fungus in a tissue culture, after a dangerous and therefore
avoided in neutropenic patient' s biopsy. The combination of the
detection of Aspergillus antigen Galactomannan (GM) in serum and
X-ray findings is considered to be an indication equivalent to a pos-
itive biopsy sample.
